Pure Global AI
NCT06093568Not yet recruiting

Delving Into Participation Trends in Renal Cell Carcinoma Studies

Exploring Engagement Dynamics Among Individuals Impacted by Renal Cell Carcinoma
Power Life Sciences Inc.ClinicalTrials.gov
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Study type
Observational
Sponsor & location
Primary sponsor
Power Life Sciences Inc.
Location
San Francisco, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2024
End date
Nov 01, 2026
Enrollment
500 participants
Primary outcome

Number of patients who decide to participate in a renal cell carcinoma clinical study,Rate of patients who remain in renal cell carcinoma clinical trial to trial completion

Summary

The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell
 carcinoma who partake in a separate clinical study featuring a specific medical intervention.
 The primary emphasis will be on meticulously tracking the rates of trial completion and
 withdrawal among these individuals.
 
 By joining this clinical trial, individuals have the unique opportunity to contribute to the
 betterment of future renal cell carcinoma patients and play an active role in advancing
 clinical research.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06093568
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06093568 through Pure Global AI's free database. This phase not specified trial is sponsored by Power Life Sciences Inc. and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.